A Phase 3 interventional study of Ceftobiprole medocaril and Daptomycin in Staphylococcus Aureus Bacteremia, sponsored by Basilea Pharmaceutica. Completed at 60 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Basilea Pharmaceutica · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).
Patients were randomized 1:1 to ceftobiprole or the comparator regimen. Randomization was stratified by study site, dialysis status, and prior antibacterial treatment use within 7 days before randomization.
The three phases of the study were:
304 studies on the registry are indexed under Staphylococcal Infections; 35 are open to participants now.
This study's enrollment of 390 is above the median of 124 across 198 interventional studies indexed under Staphylococcal Infections.
Browse Staphylococcal Infections studies →Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least one of the following signs or symptoms of bacteremia:
At least one of the following:
Exclusion Criteria:
Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril)
Drug: Ceftobiprole medocaril
Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards), with or without aztreonam
Drug: Daptomycin
Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril) as a 2 h infusion
Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards) as a 0.5 h infusion, with or without aztreonam
Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit
Comparison of overall success rates in the mITT population Overall success at PTE for the mITT population was defined as all of the following criteria being met (Responder): 1. Patient alive at Day 70 (± 5 days) post-randomization. 2. No new metastatic foci or complications of the SAB infection. 3. Resolution or improvement of SAB-related clinical signs and symptoms. 4. Two negative blood cultures for S. aureus (without any subsequent positive blood culture for S. aureus)
Time frame: PTE visit on Day 70 (± 5 days) post-randomization
Number of Patients With or Without Overall Success at the PTE Visit in the CE Population
Comparison of overall success rates in the Clinical Evaluable (CE) population Overall success at PTE for the CE population was defined as all of the following criteria being met (Responder): 1. Patient alive at Day 70 (± 5 days) post-randomization. 2. No new metastatic foci or complications of the SAB infection. 3. Resolution or improvement of SAB-related clinical signs and symptoms. 4. Two negative blood cultures for S. aureus (without any subsequent positive blood culture for S. aureus)
Time frame: At PTE visit on Day 70 (± 5 days) post-randomization
Number of Patients With Microbiological Eradication at the PTE Visit
Comparison of microbiological eradication rates in the mITT population. Microbiological eradication rate was defined as a negative blood culture for S. aureus during study treatment and another negative blood culture during the follow up period up to PTE.
Time frame: At PTE visit on Day 70 (± 5 days) post-randomization
All-cause Mortality at the PTE Visit
Comparison of all-cause mortality rates in the mITT population
Time frame: At PTE visit on Day 70 (± 5 days) post-randomization
Number of Patients With or Without New Metastatic Foci or Other Complications of SAB Developed After Day 7
Comparison of complication rates in the mITT population defined by number of patients with development of new metastatic foci or other complications of SAB after Day 7
Time frame: Assessment after Day 7 post-randomization through to post-treatment evaluation (PTE) visit on Day 70 (± 5 days)
Time to Staphylococcus Aureus Bloodstream Clearance
Time-to-event in the mITT Bloodstream clearance was defined as two consecutive study days with blood-culture-negative assessments for S. aureus, without any subsequent S. aureus relapse or reinfection
Time frame: Up to 6 weeks post-randomization
Number of Patients With or Without Adverse Events (AEs)
Treatment-emergent adverse events in the safety population
Time frame: AEs were assessed from the first dose of study drug through the post-treatment evaluation (PTE) visit on Day 70 (± 5 days)
Hospitalized male or female patients aged ≥ 18 years who had complicated Staphylococcus aureus bacteremia (SAB). SAB, based on ≥ 1 positive blood culture obtained within 72 h prior to randomization, with signs or symptoms of bloodstream infection
| Milestone | Ceftobiprole | Daptomycin |
|---|---|---|
| Started | 192 | 198 |
| Modified itt (mitt) | 189 | 198 |
| Completed | 157 | 169 |
| Not completed | 35 | 29 |
| Withdrew: Death | 17 | 18 |
| Withdrew: Withdrawal by subject | 11 | 6 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Administrative or logistical reason | 1 | 0 |
| Withdrew: The patient was transferred to another hospital | 1 | 0 |
Comparison of overall success rates in the mITT population Overall success at PTE for the mITT population was defined as all of the following criteria being met (Responder): 1. Patient alive at Day 70 (± 5 days) post-randomization. 2. No new metastatic foci or complications of the SAB infection. 3. Resolution or improvement of SAB-related clinical signs and symptoms. 4. Two negative blood cultures for S. aureus (without any subsequent positive blood culture for S. aureus)
| Participants | Ceftobiprole | Daptomycin |
|---|---|---|
| Number of responders | 132 | 136 |
| Number of non-responders | 57 | 62 |
Comparison of overall success rates in the Clinical Evaluable (CE) population Overall success at PTE for the CE population was defined as all of the following criteria being met (Responder): 1. Patient alive at Day 70 (± 5 days) post-randomization. 2. No new metastatic foci or complications of the SAB infection. 3. Resolution or improvement of SAB-related clinical signs and symptoms. 4. Two negative blood cultures for S. aureus (without any subsequent positive blood culture for S. aureus)
| Participants | Ceftobiprole | Daptomycin |
|---|---|---|
| Number of responders | 127 | 130 |
| Number of non-responders | 36 | 37 |
Comparison of microbiological eradication rates in the mITT population. Microbiological eradication rate was defined as a negative blood culture for S. aureus during study treatment and another negative blood culture during the follow up period up to PTE.
| Participants | Ceftobiprole | Daptomycin |
|---|---|---|
| Number of Patients With Microbiological Eradication at the PTE Visit | 155 | 153 |
Comparison of all-cause mortality rates in the mITT population
| Participants | Ceftobiprole | Daptomycin |
|---|---|---|
| Patients died | 17 | 18 |
| Patients alive | 172 | 180 |
Comparison of complication rates in the mITT population defined by number of patients with development of new metastatic foci or other complications of SAB after Day 7
| Participants | Ceftobiprole | Daptomycin |
|---|---|---|
| Patients with development of new metastatic foci or other complications of SAB after Day 7 | 11 | 11 |
| Patients without development of new metastatic foci or other complications of SAB after Day 7 | 178 | 187 |
Time-to-event in the mITT Bloodstream clearance was defined as two consecutive study days with blood-culture-negative assessments for S. aureus, without any subsequent S. aureus relapse or reinfection
| Days | Ceftobiprole | Daptomycin |
|---|---|---|
| Time to Staphylococcus Aureus Bloodstream Clearance | 4 (3 to 5) | 4 (3 to 5) |
Treatment-emergent adverse events in the safety population
| Participants | Ceftobiprole | Daptomycin |
|---|---|---|
| Any adverse events (AEs) | 121 | 117 |
| Any drug-related AE | 25 | 11 |
| Any severe AEs | 29 | 38 |
| Any study drug-related severe AEs | 1 | 2 |
| Any serious adverse events (SAE) | 36 | 45 |
| Any drug-related SAEs | 2 | 4 |
| Any AE leading to treatment discontinuation | 18 | 18 |
| Study drug-related AEs leading to treatment discontinuation | 9 | 3 |
| Any AE leading to death | 17 | 18 |
| Study drug-related AEs leading to death | 0 | 0 |
| Any AE of special interest (AESI) | 9 | 7 |
| Any drug-related AESI | 5 | 4 |
Collected over All AEs occurring from the start of first dosing up to and including the scheduled PTE visit on Day 70 (± 5 days) were collected.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ceftobiprole | 17/191 (8.9%) | 36/191 (18.8%) | 61/191 (31.9%) |
| Daptomycin | 18/198 (9.1%) | 45/198 (22.7%) | 45/198 (22.7%) |
| Event | Ceftobiprole | Daptomycin |
|---|---|---|
| Septic shockInfections and infestations | 4/191 | 8/198 |
| Multiple organ dysfunction syndromeGeneral disorders and administration site conditions | 4/191 | 2/198 |
| PneumoniaInfections and infestations | 3/191 | 2/198 |
| Cardiac failureCardiac disorders | 0/191 | 3/198 |
| COVID-19 pneumoniaInfections and infestations | 2/191 | 3/198 |
| Staphylococcal bacteraemiaInfections and infestations | 0/191 | 3/198 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 2/191 | 0/198 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/191 | 0/198 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/191 | 2/198 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/191 | 2/198 |
| Event | Ceftobiprole | Daptomycin |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 20/191 | 24/198 |
| NauseaGastrointestinal disorders | 20/191 | 8/198 |
| Blood potassium decreasedInvestigations | 17/191 | 5/198 |
| VomitingGastrointestinal disorders | 16/191 | 4/198 |
| Gamma-glutamyltransferase increasedInvestigations | 12/191 | 15/198 |
| DiarrhoeaGastrointestinal disorders | 13/191 | 5/198 |
The mITT (Intent-to-Treat population who received any dose of study medication) and who had a blood culture positive for staphylococcus aureus represented the Baseline Analysis Population. It comprised 387 out of the 390 patients in the ITT population.
| Age, Continuous(years) | Ceftobiprole | Daptomycin | Total |
|---|---|---|---|
| Mean | 55.5 ± 15.18 | 56.5 ± 15.33 | 56.0 ± 15.25 |
| Sex: Female, Male(Participants) | Ceftobiprole | Daptomycin | Total |
|---|---|---|---|
| Female | 128 | 140 | 268 |
| Male | 61 | 58 | 119 |
| Ethnicity (NIH/OMB)(Participants) | Ceftobiprole | Daptomycin | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 15 | 29 |
| Not Hispanic or Latino | 174 | 182 | 356 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Ceftobiprole | Daptomycin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 4 | 5 | 9 |
| White | 179 | 192 | 371 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 0 | 4 |
| Region of Enrollment(Participants) | Ceftobiprole | Daptomycin | Total |
|---|---|---|---|
| Europe | 175 | 185 | 360 |
| North America | 5 | 5 | 10 |
| Central America | 4 | 2 | 6 |
| South America | 3 | 4 | 7 |
| South Africa | 2 | 2 | 4 |
| Aztreonam treatment at baseline(Participants) | Ceftobiprole | Daptomycin | Total |
|---|---|---|---|
| Count of participants | 0 | 62 | 62 |
| Most frequent baseline categories of complicated SAB (Investigator-assessed)(Participants) | Ceftobiprole | Daptomycin | Total |
|---|---|---|---|
| Skin and skin structure infection | 116 | 121 | 237 |
| Intra-abdominal abscess | 26 | 29 | 55 |
| Chronic dialysis | 24 | 25 | 49 |
| Septic arthritis | 22 | 19 | 41 |
| Persistent SAB | 16 | 16 | 32 |
| Osteomyelitis | 13 | 17 | 30 |
| Definite right-sided endocarditis | 15 | 10 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2018 to primary completion in Mar 2022, 42 months.
Results were first posted in May 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ceftobiprole medocaril